ANA773 is the company’s investigational oral TLR7 agonist prodrug. In part B of the study, patients in the first cohort will receive 800mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800mg cohort.
Anadys expects to have viral load data from the 800mg cohort in the first quarter of 2009 and a complete data set in the second quarter of 2009.
Steve Worland, president and CEO of Anadys, said: “The initiation of patient dosing in this study of ANA773 marks the second study that Anadys has initiated in hepatitis C virus (HCV) patients this quarter, having commenced patient dosing earlier this week with ANA598, our non-nucleoside polymerase inhibitor. With two independent and potentially complementary HCV programs advancing toward viral load data, we look forward to demonstrating the breadth of our portfolio in this important therapeutic area.”